Key pathway inhibitors—including MCC950 (targeting the NLRP3 inflammasome) and VX-765 (a caspase-1 inhibitor)—have shown therapeutic potential in animal models but are limited by suboptimal pharmacokinetics, poor tissue specificity, and risks of immunosuppression and infection during long-term use. This evidence concerns the gene NLRP3 and infection.